标题
Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer
作者
关键词
-
出版物
BJU INTERNATIONAL
Volume 110, Issue 11, Pages 1729-1735
出版商
Wiley
发表日期
2012-08-29
DOI
10.1111/j.1464-410x.2012.11456.x
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer
- (2011) Brett S. Carver et al. CANCER CELL
- Combination of PI3K/mTOR Inhibitors: Antitumor Activity and Molecular Correlates
- (2011) M. Mazzoletti et al. CANCER RESEARCH
- Intratumoral De Novo Steroid Synthesis Activates Androgen Receptor in Castration-Resistant Prostate Cancer and Is Upregulated by Treatment with CYP17A1 Inhibitors
- (2011) C. Cai et al. CANCER RESEARCH
- Secondary Hormonal Therapy in Men With Castration-Resistant Prostate Cancer
- (2011) Mari Nakabayashi et al. Clinical Genitourinary Cancer
- Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy
- (2011) Changmeng Cai et al. ENDOCRINE-RELATED CANCER
- Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma
- (2011) Camillo Porta et al. EUROPEAN JOURNAL OF CANCER
- Rapamycin passes the torch: a new generation of mTOR inhibitors
- (2011) Don Benjamin et al. NATURE REVIEWS DRUG DISCOVERY
- PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs
- (2011) B Weigelt et al. ONCOGENE
- Prolonging hormone sensitivity in prostate cancer xenografts through dual inhibition of AR and mTOR
- (2010) A Schayowitz et al. BRITISH JOURNAL OF CANCER
- Phase 3 trial of everolimus for metastatic renal cell carcinoma
- (2010) Robert J. Motzer et al. CANCER
- Integrative Genomic Profiling of Human Prostate Cancer
- (2010) Barry S. Taylor et al. CANCER CELL
- Everolimus
- (2010) P. J. Houghton CLINICAL CANCER RESEARCH
- Inhibition of Tumor Growth Progression by Antiandrogens and mTOR Inhibitor in a Pten-Deficient Mouse Model of Prostate Cancer
- (2009) W. Zhang et al. CANCER RESEARCH
- mTOR Inhibitor RAD001 (Everolimus) Has Antiangiogenic/Vascular Properties Distinct from a VEGFR Tyrosine Kinase Inhibitor
- (2009) H. A. Lane et al. CLINICAL CANCER RESEARCH
- Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition
- (2009) M. Breuleux et al. MOLECULAR CANCER THERAPEUTICS
- Maintenance of Intratumoral Androgens in Metastatic Prostate Cancer: A Mechanism for Castration-Resistant Tumor Growth
- (2008) R. B. Montgomery et al. CANCER RESEARCH
- Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors
- (2008) Josep Tabernero et al. JOURNAL OF CLINICAL ONCOLOGY
- Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group
- (2008) Howard I. Scher et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
- Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival
- (2008) Y Wang et al. ONCOGENE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search